rs753393344
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_133510.4(RAD51B):c.452+3A>G variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000523 in 1,586,778 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_133510.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD51B | NM_133510.4 | c.452+3A>G | splice_region_variant, intron_variant | ENST00000471583.6 | NP_598194.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51B | ENST00000471583.6 | c.452+3A>G | splice_region_variant, intron_variant | 1 | NM_133510.4 | ENSP00000418859.1 |
Frequencies
GnomAD3 genomes AF: 0.0000462 AC: 7AN: 151482Hom.: 0 Cov.: 27
GnomAD3 exomes AF: 0.0000864 AC: 20AN: 231560Hom.: 0 AF XY: 0.0000797 AC XY: 10AN XY: 125540
GnomAD4 exome AF: 0.0000530 AC: 76AN: 1435296Hom.: 0 Cov.: 33 AF XY: 0.0000490 AC XY: 35AN XY: 713890
GnomAD4 genome AF: 0.0000462 AC: 7AN: 151482Hom.: 0 Cov.: 27 AF XY: 0.0000406 AC XY: 3AN XY: 73968
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 30, 2024 | The c.452+3A>G intronic variant results from an A to G substitution 3 nucleotides after coding exon 4 in the RAD51B gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may result in the creation or strengthening of a novel splice donor site. Based on the available evidence, the clinical significance of this variant remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 26, 2023 | - - |
Hereditary cancer-predisposing syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | University of Washington Department of Laboratory Medicine, University of Washington | Oct 22, 2019 | This variant was predicted to disrupt a splice donor site, resulting in skipping of exon 5 and production of abnormally short protein. This variant has been reported in a patient with a family history of breast cancer and loss of RAD51B expression (Golmard 2013). However, this variant is found in approximately 1/6000 individuals in the population. It has also been detected in three women over age 70 with no history of cancer (https://whi.color.com/) and 20 individuals in an unaffected control population (gnomAD). The presence of this variant at this frequency in unaffected women indicates that it does not substantially increase cancer risk. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at